Acorah Software Products - Accounts Production 15.0.600 false true 31 October 2022 1 November 2021 false 1 November 2022 31 October 2023 31 October 2023 09803003 Mr Paul McConnell Mrs Edwina McMillan Mr Ian Moore Mr Samantha Ormrod Mr Shaun Fahy Mr Paul McConnell iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 09803003 2022-10-31 09803003 2023-10-31 09803003 2022-11-01 2023-10-31 09803003 frs-core:CurrentFinancialInstruments 2023-10-31 09803003 frs-core:Non-currentFinancialInstruments 2023-10-31 09803003 frs-core:FurnitureFittings 2023-10-31 09803003 frs-core:FurnitureFittings 2022-11-01 2023-10-31 09803003 frs-core:FurnitureFittings 2022-10-31 09803003 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2023-10-31 09803003 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2022-11-01 2023-10-31 09803003 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2022-10-31 09803003 frs-core:PlantMachinery 2023-10-31 09803003 frs-core:PlantMachinery 2022-11-01 2023-10-31 09803003 frs-core:PlantMachinery 2022-10-31 09803003 frs-core:RevaluationReserve 2022-10-31 09803003 frs-core:RevaluationReserve 2023-10-31 09803003 frs-core:ShareCapital 2023-10-31 09803003 frs-core:RetainedEarningsAccumulatedLosses 2023-10-31 09803003 frs-bus:PrivateLimitedCompanyLtd 2022-11-01 2023-10-31 09803003 frs-bus:FilletedAccounts 2022-11-01 2023-10-31 09803003 frs-bus:SmallEntities 2022-11-01 2023-10-31 09803003 frs-bus:AuditExempt-NoAccountantsReport 2022-11-01 2023-10-31 09803003 frs-bus:SmallCompaniesRegimeForAccounts 2022-11-01 2023-10-31 09803003 frs-bus:Director1 2022-11-01 2023-10-31 09803003 frs-bus:Director2 2022-11-01 2023-10-31 09803003 frs-bus:Director3 2022-11-01 2023-10-31 09803003 frs-bus:Director4 2022-11-01 2023-10-31 09803003 frs-bus:Director5 2022-11-01 2023-10-31 09803003 frs-bus:CompanySecretary1 2022-11-01 2023-10-31 09803003 frs-countries:EnglandWales 2022-11-01 2023-10-31 09803003 2021-10-31 09803003 2022-10-31 09803003 2021-11-01 2022-10-31 09803003 frs-core:CurrentFinancialInstruments 2022-10-31 09803003 frs-core:Non-currentFinancialInstruments 2022-10-31 09803003 frs-core:RevaluationReserve 2022-10-31 09803003 frs-core:ShareCapital 2022-10-31 09803003 frs-core:RetainedEarningsAccumulatedLosses 2022-10-31
Registered number: 09803003
Apollo Pharma Ltd
Unaudited Financial Statements
For The Year Ended 31 October 2023
The Accountants
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 09803003
2023 2022
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 150,078 200,235
150,078 200,235
CURRENT ASSETS
Stocks 5 170,666 82,119
Debtors 6 305,737 234,517
Cash at bank and in hand 22,999 (882 )
499,402 315,754
Creditors: Amounts Falling Due Within One Year 7 (562,738 ) (367,676 )
NET CURRENT ASSETS (LIABILITIES) (63,336 ) (51,922 )
TOTAL ASSETS LESS CURRENT LIABILITIES 86,742 148,313
Creditors: Amounts Falling Due After More Than One Year 8 (169,018 ) (141,213 )
NET (LIABILITIES)/ASSETS (82,276 ) 7,100
CAPITAL AND RESERVES
Called up share capital 9 332,000 332,000
Revaluation reserve 10 157,830 157,830
Profit and Loss Account (572,106 ) (482,730 )
SHAREHOLDERS' FUNDS (82,276) 7,100
Page 1
Page 2
For the year ending 31 October 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Paul McConnell
Director
31/10/2024
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Apollo Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 09803003 . The registered office is Unit 1 Irwell Works, Lower Woodhill Rd, Bury, BL9 1AA.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Leasehold 11% SL
Plant & Machinery 15% RB and 33% RB
Fixtures & Fittings 33% RB
2.4. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 22 (2022: 15)
22 15
4. Tangible Assets
Land & Property
Leasehold Plant & Machinery Fixtures & Fittings Total
£ £ £ £
Cost
As at 1 November 2022 242,653 312,854 4,460 559,967
As at 31 October 2023 242,653 312,854 4,460 559,967
Depreciation
As at 1 November 2022 134,808 222,224 2,700 359,732
Provided during the period 26,961 22,615 581 50,157
As at 31 October 2023 161,769 244,839 3,281 409,889
...CONTINUED
Page 3
Page 4
Net Book Value
As at 31 October 2023 80,884 68,015 1,179 150,078
As at 1 November 2022 107,845 90,630 1,760 200,235
5. Stocks
2023 2022
£ £
Stock 170,666 82,119
6. Debtors
2023 2022
£ £
Due within one year
Trade debtors 250,737 179,517
Other debtors 55,000 55,000
305,737 234,517
7. Creditors: Amounts Falling Due Within One Year
2023 2022
£ £
Trade creditors 264,711 131,228
Bank loans and overdrafts 10,000 53,532
Other creditors 120,990 110,145
Taxation and social security 167,037 72,771
562,738 367,676
8. Creditors: Amounts Falling Due After More Than One Year
2023 2022
£ £
Bank loans 169,018 141,213
9. Share Capital
2023 2022
£ £
Allotted, Called up and fully paid 332,000 332,000
10. Reserves
Revaluation Reserve
£
As at 1 November 2022 157,830
As at 31 October 2023 157,830
Page 4